The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis

被引：40

作者：

Katz-Agranov, Nurit ^{[1
]}

Khattri, Saakshi ^{[2
]}

Zandman-Goddard, Gisele ^{[1
,3
]}

机构：

[1] Wolfson Med Ctr, Dept Med C, IL-58100 Holon, Israel

[2] Rockefeller Univ, Mt Sinai Hosp, Lab Invest Dermatol, New York, NY USA

[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel

来源：

AUTOIMMUNITY REVIEWS | 2015年 / 14卷 / 08期

关键词：

Rheumatoid arthritis; IVIG; Vasculitis; Rhupus syndrome; Severe infections; Adult Still's disease; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GAMMA-GLOBULIN THERAPY; RECURRENT MISCARRIAGE; AUTOIMMUNE-DISEASES; SYNOVIAL FIBROBLASTS; MARKED IMPROVEMENT; JOINT DESTRUCTION; FELTYS-SYNDROME; CASE SERIES; NK CELLS;

D O I：

10.1016/j.autrev.2015.04.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Intravenous immunoglobulins (IVIGs) are beneficial and safe for various diseases other than primary immunodeficiencies. Over the years, IVIG has been given for autoimmune diseases as an off-label adjunct therapy. While other biologic agents are indicated for rheumatoid arthritis (RA), IVIG may have a role for specific subgroups of RA patients where anti-cytokine blockers or rituximab may be unwarranted. Such subgroups may include patients with vasculitis, overlap rhupus syndrome, severe infections with active disease, and pregnancy. In addition, IVIG may be considered for juvenile chronic arthritis (JCA) and adult Still's disease. We review the literature for IVIG treatment in RA patients and for these subgroups. (C) 2015 Elsevier B.V. All rights reserved.

引用

页码：651 / 658

页数：8

共 120 条

[1] HIGH-DOSE IMMUNOGLOBULIN IN FELTYS SYNDROME [J].

AHERN, M ;

HARKNESS, J ;

MADDISON, P ;

FORSKITT, S .

ANNALS OF THE RHEUMATIC DISEASES, 1983, 42 (04) :476-477

[2] Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock [J].

Alejandria, Marissa M. ;

Lansang, Mary Ann D. ;

Dans, Leonila F. ;

Mantaring, Jacinto Blas, III .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (09)

[3] Efficacy and tolerability of rituximab in patients with rhupus [J].

Andrade-Ortega, Lilia ;

Irazoque-Palazuelos, Fedra ;

Munoz-Lopez, Sandra ;

Rosales-Don Pablo, Victor Manuel .

REUMATOLOGIA CLINICA, 2013, 9 (04) :201-205

[4] Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis [J].

Baecklund, E ;

Iliadou, A ;

Askling, J ;

Ekborn, A ;

Backlin, C ;

Granath, F ;

Catrina, AT ;

Rosenquist, R ;

Feltelius, N ;

Sundström, C ;

Klareskog, L .

ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :692-701

[5] Felty's syndrome [J].

Balint, GR ;

Balint, PV .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (05) :631-645

[6]

Ballanti E, 2012, ISR MED ASSOC J, V14, P583

[7] The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders [J].

Ballow, Mark .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) :315-323

[8] Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy [J].

Barbhaiya, Medha ;

Bermas, Bonnie L. .

CLINICAL IMMUNOLOGY, 2013, 149 (02) :225-235

[9] Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis [J].

Bartok, Beatrix ;

Firestein, Gary S. .

IMMUNOLOGICAL REVIEWS, 2010, 233 :233-255

[10] A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? [J].

Benoist, C ;

Mathis, D .

ARTHRITIS RESEARCH, 2000, 2 (02) :90-94

← 1 2 3 4 5 6 7 8 9 10 →